𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical trial accrual among new cancer patients at a community-based cancer center : A prospective study

✍ Scribed by Ronald S. Go; Kathleen A. Frisby; Jennifer A. Lee; Michelle A. Mathiason; Christine M. Meyer; Jodi L. Ostern; Sara M. Walther; Jonean E. Schroeder; Lori A. Meyer; Kathryn E. Umberger


Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
122 KB
Volume
106
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACKGROUND

To the authors' knowledge, only limited data are available regarding clinical trial accrual patterns and the barriers encountered among newly diagnosed patients seen at community‐based cancer centers.

METHODS

In the current study, the authors prospectively collected clinical and sociodemographic data from all adult patients seen at a community‐based cancer center who had new cancers diagnosed between 2003–2004. Clinical trial enrollment decisions were noted and factors that prevented accrual were identified.

RESULTS

There was a total of 1012 new cancer patients. In 587 patients (58%), clinical trials appropriate for the diagnosis and stage of disease were not available. Among those patients for whom trials were available, 19.8% did not meet eligibility criteria, and only 9.9% of patients were enrolled. Although more trials were found to be available for women compared with men (51% vs. 32%; P < 0.01), the accrual rates were equal (11.2% vs. 7.6%; P = 0.24). Elderly patients comprised approximately 59.4% of those patients with available trials, but they were less likely to be enrolled (5.1% vs. 16.8%; P < 0.01). The major barriers to nonparticipation can be grouped into protocol limitations (68.1%), physician triage (16%), and patient decisions (15.9%). The overall accrual rate when all patients were included was 4% (42 of 1012 patients).

CONCLUSIONS

At the study institution, participation in clinical trials is reported to be low. The unavailability of appropriate clinical trials represents the most significant barrier. Continuing efforts to encourage physicians and to educate patients remain necessary. If the current study findings are found to be applicable to other community‐based cancer centers, making a larger variety of clinical trials available to the community may help to improve the accrual of patients to national cancer clinical trials. Cancer 2006. Β© 2005 American Cancer Society.


πŸ“œ SIMILAR VOLUMES


A phase 3 randomized, placebo-controlled
✍ Pascal Jean-Pierre; Gary R. Morrow; Joseph A. Roscoe; Charles Heckler; Supriya M πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 187 KB πŸ‘ 1 views
Cancer patients' expectations of experie
✍ Maarten Hofman; Gary R. Morrow; Joseph A. Roscoe; Jane T. Hickok; Karen M. Musti πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 90 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Adequate management of treatment‐related side effects is important for patients and challenging for clinicians. Side effects generated by various treatments have been characterized reasonably well. However, to the authors' knowledge, less is known regarding what patients

Nausea and emesis remain significant pro
✍ Jane T. Hickok; Joseph A. Roscoe; Gary R. Morrow; David K. King; James N. Atkins πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 93 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Clinical reports suggest that nausea remains a side effect of chemotherapy despite widespread use of serotonin receptor antagonists. This study summarized the frequency, timing, and intensity of postchemotherapy nausea for patients receiving doxorubicin, cisplatin, or car